Irem Ozkan-Dagliyan

Department of Pharmacology University of North Carolina, Chapel Hill, Chapel Hill, NC 
Cancer biology
"Irem Ozkan-Dagliyan"
Mean distance: (not calculated yet)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Diehl JN, Hibshman PS, Ozkan-Dagliyan I, et al. (2021) Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer. Advances in Cancer Research. 153: 101-130
Ozkan-Dagliyan I, Diehl JN, George SD, et al. (2020) Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers. Cell Reports. 31: 107764
Vaseva AV, Blake DR, Gilbert TSK, et al. (2018) KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism. Cancer Cell. 34: 807-822.e7
Dagliyan O, Krokhotin A, Ozkan-Dagliyan I, et al. (2018) Computational design of chemogenetic and optogenetic split proteins. Nature Communications. 9: 4042
Waters AM, Ozkan-Dagliyan I, Vaseva AV, et al. (2017) Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies. Science Signaling. 10
Ye R, Selby CP, Chiou YY, et al. (2014) Dual modes of CLOCK:BMAL1 inhibition mediated by Cryptochrome and Period proteins in the mammalian circadian clock. Genes & Development. 28: 1989-98
Ozkan-Dagliyan I, Chiou YY, Ye R, et al. (2013) Formation of Arabidopsis Cryptochrome 2 photobodies in mammalian nuclei: application as an optogenetic DNA damage checkpoint switch. The Journal of Biological Chemistry. 288: 23244-51
See more...